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Abstract
Background: Suicide is a major cause of preventable death, and suicidal behaviour is prevalent in acute psychiatric
wards. People admitted to acute psychiatric wards often experience repeated episodes of suicidal behaviour,
causing great distress and heavy use of NHS services. There is little research investigating effective psychological
treatments for suicidal patients in inpatient settings although previous research has found support for psychological
therapies which specifically target suicidal behaviour. This paper describes the protocol of a single blind RCT to
investigate the acceptability and feasibility of a cognitive behavioural intervention targeting suicidality (CBSP) for
suicidal people in acute psychiatric wards.
Methods/Design: A single blind RCT comparing treatment as usual (TAU) to TAU plus Cognitive Behavioural
Suicide Prevention (CBSP) therapy (TAU + CBSP). Sixty participants (aged 18–65 years) who are suicidal, or have
been within the past 3 months, will be recruited from NHS trusts in the North West of England. Our primary
objective is to determine whether CBSP is feasible, acceptable and efficacious when compared to patients who
receive TAU alone. Secondary aims are the impact of CBSP on suicidal thinking, behaviours, functioning, quality of
life, service use and psychological factors associated with suicide. Assessments take place at baseline, 6 weeks and
6 months (end of treatment). The analysis will report on the feasibility and acceptability of CBSP. Qualitative data
from staff and service users will inform feasibility and acceptability data.
Discussion: Psychiatric inpatients are a high-risk group and the use of psychological therapies in these settings is
rare and requires evaluation. This study is essential to investigate the unique contextual challenges involved in
delivering psychological therapy to suicidal inpatients and to identify any necessary modifications required within
inpatient settings. The findings will inform a larger, definitive trial.
Trial registration: 15 March 2012, PB-PG-1111-26026, NIHR ISRCTN17890126.
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Background
Suicide is a major cause of preventable death. Between
2003 and 2013 in England, there were 49,251 deaths in
the general population that received a suicide or ‘un-
determined verdict’, i.e. a death from an undetermined
cause at inquest, an average of 4477 per year [1]. In
2013, 6233 people died by suicide in the UK with 11.9
deaths from suicide per 100,000 people within the gen-
eral population [2]. Seventy-eight per cent of all suicides
in 2013 were male and suicide remains the leading cause
of death for males aged between 20–34 and 35–49 [2].
It is estimated that 90 % of suicides are carried out by
people with mental health difficulties [3] and many of
these people are under the care of mental health services
and have received inpatient care. In England, between
2002 and 2011, 63 % of patients who died by suicide had
a mental health diagnosis [4]. During 2003 and 2013,
there were 13,972 deaths (28 % of the general population
suicides) identified as patient suicides (i.e. the person
had been in contact with mental health services in the
12 months prior to death), which is an average of 1270
patient suicides per year [1]. In the same period, there
were 1295 inpatient deaths by suicide (9 % of patient
suicides), an average of 118 suicides per year. The first
week of admission to a psychiatric inpatient ward is a
high-risk period, with approximately one quarter of in-
patient suicides occurring within this first week [5].
However, the post-discharge period has also been identi-
fied as a high-risk time for suicide among mental health
patients, particularly the first few days after leaving hos-
pital [6]. The National Confidential Inquiry into Suicide
and Homicides reported 2368 suicides within 3 months
of discharge from inpatient care (17 % of all patient sui-
cides), which is an average of 215 suicides per year [1].
Suicidality also has a substantial economic impact.
Treatment costs associated with suicidal behaviour are
significant, with inpatient psychiatric care accounting for
nearly 70 % of NHS costs [7]. In 2013–2014, over
105,000 patients received treatment in NHS psychiatric
wards and readmission is commonplace [8]. Whilst the
median length of stay was 23 days, at the end of 2013
more than 50 % of people in hospital have been there for
over 117 days [8]. Current methods of recording clinical
data do not identify the specific cost of treating suicidal
behaviour in inpatient settings, so the true economic bur-
den remains unclear [7]. There are economic benefits
from delaying completed suicide as the number of lost
years of productive activity will be reduced; overall it is es-
timated that averted costs are of £66,797 per year per per-
son of working age where suicide is delayed [7].
In addition to completed suicides, suicidal behaviour is
frequently a recurring experience rather than an isolated
singular event [9, 10] and suicidality (referring to sui-
cidal thoughts and behaviours) is often a reason for
admission to an acute psychiatric ward. Given that sui-
cidal behaviour is highly prevalent in acute psychiatric
wards, and there is a high-risk period following dis-
charge from inpatient wards, there is a need to identify
treatments which reduce the likelihood of suicidality in
these settings and in the post-discharge period.
Inpatient wards are known to be complex and challen-
ging environments for staff and patients alike. Recent re-
ports from the Royal College of Psychiatrists [11], the
Care Quality Commission [12] and the Schizophrenia
Commission [13] highlight low qualified staff/patient ra-
tios, reliance on agency staff, lack of skills in care, and in-
sufficient clinical supervision and training. This creates a
custodial culture with limited opportunities for staff/pa-
tient engagement in therapeutic relationships focused on
recovery. A recent study identified that 49 % of acute ward
staff were emotionally exhausted, with 29 % showing psy-
chological distress [14]. This highlights the significant
challenges in implementing effective interventions in in-
patient settings.
There are a number of local and national policies aimed
at reducing suicide, particularly for people deemed at high
risk, for example for people with mental health difficulties
and for patients on acute psychiatric wards [15]. However,
suicide rates and suicidal behaviours remain high and
whilst there is a considerable body of research investigat-
ing the epidemiological risk factors for suicide, there is
very little examining psychological treatment for suicidal-
ity in inpatient settings.
However, there is good evidence supporting the use of
psychological treatments such as cognitive behaviour ther-
apy (CBT) for suicidality in other settings [16, 17]. CBT
has an extensive evidence base, has been shown to be effi-
cacious and acceptable to patients and is a recommended
intervention by NICE for a number of mental health con-
ditions. In 2011, NICE released guidelines recommending
CBT for longer-term treatment of self-harm [15]. Several
approaches have been evaluated [17, 18]: however, none
have focused on delivery within inpatient settings. Tarrier
and colleagues [19] developed Cognitive Behavioural Pre-
vention for Suicidality in Psychosis (CBSP), utilising the
principles of CBT and targeting specific psychological pro-
cesses that drive suicidality for use with complex clients.
This therapy offers a structured intervention to address
and amend the specific psychological architecture of sui-
cidal behaviour. A community-based trial with people
with schizophrenia showed that the treatment was suc-
cessful in reducing suicidal ideation and suicide probabil-
ity in a population with psychosis [17] and early findings
from a further study involving suicidal prisoners look
promising [20] and show CBSP to be feasible and accept-
able with complex clients experiencing suicidal ideation.
CBSP is underpinned by the Schematic Appraisal
Model of Suicide (SAMS) which is a dynamic model to
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help understand and guide psychological suicide preven-
tion interventions [21]. The SAMS model explains how
dysfunctional psychological processes lead to the forma-
tion of a ‘suicide schema’ (a core belief that becomes a
habitual memory). Each episode of suicide crisis exerts a
‘kindling’ effect that strengthens the latent ‘suicide
schema’, reinforcing more entrenched and elaborate
plans. Each repetition increases the ease of schema acti-
vation, and, in turn, suicidal behaviour. This approach
has not yet been evaluated with psychiatric inpatients
experiencing suicidal behaviour.
Given that there are such high levels of suicidality within
acute psychiatric wards and post discharge, there is a need
to ascertain whether psychological treatments can be ef-
fective in reducing suicidality in this population. As there
is growing evidence supporting the use of CBSP, the pri-
mary objective of the current trial is to explore whether
CBSP is feasible and acceptable for service users and staff
on acute inpatient psychiatric wards. Secondary objectives
are to assess the impact of the intervention on suicide be-
haviour and ideation, functioning, quality of life, NHS ser-
vice use and other psychological variables thought to be
predictive of suicide. Qualitative data from staff and pa-
tients after the intervention will be used to assess feasibil-
ity and acceptability of the intervention and will help in




The Inpatient Suicide Intervention and Therapy Evaluation
(INSITE) trial is designed as a single blind randomised con-
trolled trial (RCT) with participants recruited from acute
psychiatric wards from NHS trusts in the North West of
England, UK. Sixty participants will be recruited and ran-
domly allocated, using an independent source, to treatment
as usual (TAU) or to TAU plus 20 sessions of Cognitive
Behavioural Suicide Prevention Therapy (CBSP). TAU con-
sists of medical and nursing care and medication as appro-
priate, plus multidisciplinary team management during
inpatient stay. Following discharge, TAU would be variable
depending on patients’ needs but typically would consist of
multidisciplinary team management of community mental
health team. Participants will be followed up at 6 weeks
and 6 months (post intervention). The end of treatment is
a fixed time and does not vary depending on treatment
progress.
The project runs over three phases using a mixed-
methods approach following the Medical Research
Council’s (MRC’s) framework for developing complex
interventions.
In phase 1, we conducted qualitative data collection from
staff (n = 20) and patients (n = 20) investigating their views
of inpatient care and on the implementation of CBSP,
which has been used to inform the treatment and imple-
mentation protocol of the RCT. Phase 2 is the RCT evalu-
ating CBSP reported here. Phase 3 will involve qualitative
evaluation of staff and patient experiences and views of
CBSP. A purposive sample of patients from both arms of
the RCT will be sought to elicit a broad range of views re-
garding CBSP. This will include a balance of participants
who have had a good outcome, those who have dropped
out of the intervention and control participants. Interviews
will explore participants’ and staff experiences and expecta-
tions of therapy, views on the content of CBSP and facilita-
tors and barriers to implementation of the approach within
inpatient settings. Informed consent will be obtained from
all participants.
Ethics and governance
The INSITE study is supported by the NIHR Research for
Patient Benefit Programme (NIHR RfPB, grant number
PB-PG-1111-26026). The study has been approved by the
NRES Committee North West – Lancaster (registration
number 13/NW/0504) and is conducted following guide-
lines of Good Clinical Practice (GCP) in accordance with
the principles of the Declaration of Helsinki. The study is
also being carried out in collaboration with the Samaritans
and a local branch of Mind. Trial monitoring is carried
out through the host trust, Manchester Mental Health
and Social Care Trust, and the trial is overseen by an inde-
pendent trial steering group consisting of academics, ser-
vice users, carers and a statistician. In addition, a Service
User Reference Group consisting of up to eight members
who have previous experience of inpatient suicidality con-
tribute to the design and execution of the trial. They pro-
vide monthly ongoing advice to the research team
throughout the trial
Inclusion criteria
Participants who are between the ages of 18 and 65 years
of age, are current inpatients of an acute psychiatric ward,
are able to provide informed consent, have experienced
suicidal thoughts or behaviours within the 3 months prior
to admission (as evidenced by ward staff report and con-
firmed by self-report and case note review following con-
sent) and have sufficient English language capacity, are
included.
Recruitment and randomisation
Recruitment is over an 18-month period from May 2014
to the end of 2015. Eligible participants are identified by
inpatient ward staff approached by trained research as-
sistants or clinical studies officers from the Comprehen-
sive Research Network (CRN). Participants deemed
eligible to participate are provided with an information
sheet detailing involvement in the trial and informed
consent is taken 24 hours later should they wish to take
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part. Research assistants carry out a battery of assessments
following which participants are randomly assigned to ei-
ther TAU or TAU plus CBSP. Randomisation is
statistician-led and pseudo-random, carried out using
Sealed Envelope© Software [22] with group stratification
by gender and history of self-harm. Allocation conceal-
ment is ensured as participant randomisation codes are
not revealed until the participant is recruited into the trial.
Participants are followed up by research assistants blinded
to treatment allocation at 6 weeks and 6 months following
baseline assessment. Procedures for maintaining blindness
are developed for the trial, including steps and actions
taken to ensure the blinding process is conducted
correctly and to avoid jeopardising the blinding of the re-
search assistant. During assessment participants are
reminded by the research assistant to not disclose their
treatment allocation. Blindness is monitored by the trial
project coordinator who is not blinded to treatment and
manages all follow-up appointments. Where blind
breaches occur prior to follow-up appointments, subse-
quent data collection is allocated to an alternative research
assistant to ensure all follow-up data is collected by blind
assessors.
Intervention
The intervention consists of TAU plus 20 CBSP sessions
of up to 1-hour duration, over 6 months. Participants who
are discharged during the treatment envelope continue
their sessions in the community. TAU includes usual
nursing and medical care during the inpatient stay, includ-
ing medication and assessments, reviews and evaluation
by the ward team. Following discharge from the ward,
TAU is overseen by the appropriate care professional (e.g.
care coordinator, GP, psychiatrist) and usually involves
medical and multidisciplinary review and monitoring. Psy-
chological therapies may also be offered to some partici-
pants as part of their TAU and this will be monitored.
CBSP will be delivered once or twice weekly during the
participants’ inpatient stay and will continue at weekly in-
tervals following discharge into the community. The inter-
vention is guided by a detailed treatment protocol based
on the original CBSP treatment protocol [19] but refined
for use with inpatients by the project team and from data
informed from pre-trial staff and patient qualitative inter-
views. CBSP is a recovery-based intervention, based on a
detailed understanding of the individual’s experiences
which aims to address and reduce the processes involved
in ‘suicide schema’ activation, maintenance and elabor-
ation using cognitive behavioural approaches. Therapy is
carried out by clinical psychologists meeting the British
Association of Behavioural and Cognitive Psychotherapies
minimum standards for CBT practice. Treatment fidelity
is maintained through adherence to a detailed treatment
protocol and weekly supervision. In addition, therapy
sessions are audio-recorded where permission to do so is
granted. These are rated by the supervisory team, using
the Cognitive Therapy Scale for Psychosis [23], to ensure
therapists are adhering to CBT principles. Following the
conclusion of the trial, a sample of recorded sessions will
be subject to an independent fidelity check carried out by
an external expert not involved in the trial.
Primary outcome measures
The primary outcome is feasibility and acceptability of
the intervention. Outcomes will be measured by uptake
and attendance of therapy sessions during the inpatient
stay and following discharge (a minimum of 10 sessions
attended will be accepted as success), time spent in ther-
apy, attrition (we anticipate a 20 % attrition rate based
on similar RCTs with complex populations) and thera-
peutic alliance. The acceptability of the intervention and
user views will be explored in phase 3 through semi-
structured individual interviews with a purposive sample
of participants and staff at the end of the intervention.
Secondary outcomes
Secondary outcomes include measures of suicidal idea-
tion, psychopathology, functioning, service use (to in-
form health economy data) and psychological variables
associated with prediction of suicide:
1. Measures of the intensity and duration of suicidal
ideation, and suicidal plans and behaviour have
been selected to reflect the continuum of suicidality
from thoughts through to behaviours. Each of the
measures will be completed at baseline, 6 weeks and
6 months following baseline assessment (end of
treatment):
a. The Beck Scale for Suicidal Ideation (BSSI) is a
21-item self-report scale evaluating suicidal
ideation, planning and intent over the last
week [24]. The scale has good reliability and
validity [24]
b. The Suicidal Behaviours Questionnaire-revised
(SBQ-R) is a 4-item measure used extensively in
clinical settings to establish risk of suicide, revised
to report on suicidality in the past 3 months [25].
The scale has good reliability and validity in
clinical and non-clinical samples [25]
c. The Suicide Probability Scale (SPS) is an 18-item
self-report scale indicating further suicide
behaviour probability. The scale has good internal
consistency and test-retest reliability [26]
d. The Beck Hopelessness Scale (BHS) is a 20-item
self-report tool, measuring negative beliefs about
the future over three domains of hopelessness
over a week [27]. Total scores range from 0–20
with higher scores indicating higher levels of
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hopelessness and is widely used in clinical
settings. There is strong evidence for the scale’s
convergent validity and internal consistency in
clinical populations [28]
e. Review of Clinical Records. This review will be
conducted by a member of the research team to
identify number of episodes of suicidal behaviour
from the case records
2. Psychopathology:
a. The Positive and Negative Syndrome Scale
(PANSS) [29], is an interviewer-based scale
which includes scales of positive symptoms,
negative symptoms and general psychopathology
and is used widely in mental health research. The
scale has good internal reliability and concurrent
validity [30]
b. The Psychotic Symptoms Rating Scales (PSYRATS)
is a well-validated assessment of the frequency
and intensity of hallucinations and delusions in
psychosis and associated distress. The scale has
excellent psychometric properties with inter-
rater reliability for the scales ranging between
0.78–1.0 [31]
c. The Calgary Depression Scale (CDS) [32]
is a 9-item observer-rated measure specifically
designed for people with severe mental
health problems, minimising contamination
by negative symptoms and the extrapyramidal
side effects
of neuroleptics. The scale has high inter-rater
reliability and discriminant validity [33]
d. Sleep Condition Indicator (SCI) is an 8-item scale
measuring quality of sleep over the period of a
month. Sleep disturbances have been linked to a
number of psychopathologies. The SCI is valid,
reliable and sensitive to change in insomnia
severity [34]
3. Functioning:
a. Personal and Social Performance Scale (PSP) is an
interviewer-rated scale which assesses personal
and social functioning over four domains via a
semi-structured interview [35]. The scale has
adequate internal consistency reliability and is
sensitive to differences in social functioning [36]
4. Quality of life:
a. WHO Quality of Life-Brief (WHOQOL-Brief ) is
26-item self-report scale which measure the
following domains: physical health, psychological
health, social relationships and environment
[37]. Confirmatory factor analyses of
internal consistency, item-total correlations,
discriminant validity and construct validity
indicate that the scale has good to excellent
psychometric properties of reliability [38]
5. Negative self-appraisals and other psychological
variables associated with suicide:
a. The Defeat Scale is a 16-item scale assessing
defeat, failed struggle and low social rank over
the last 7 days [39]
b. The Entrapment Scale is a 16-item, self-report
scale assessing feelings of being trapped by
internal and external events in the past 7 days.
The entrapment and defeat measures have good
psychometric properties and significantly
correlate with depression [39]
c. The Self-Concept Questionnaire (SCQ) is a
self-report measure of seven components of
self-esteem using 30 items [40]. Investigation
of convergent and discriminant validity are
encouraging [40]. The SCQ has high reliability and
good concurrent and discriminant validity [41]
d. Coping in Stressful Situations (CSS) is a 48-item
measure that assesses three types of coping styles
[42]. The inventory has excellent psychometric
properties [42, 43]
6. Service user and staff perceptions of acute inpatient
wards (at baseline and 6 months only):
a. Views on Inpatient Care (VOICE-Patient measure)
is a 19-item questionnaire exploring service
users’ experience of inpatient wards. The
measure has good validity and internal and
test-retest reliability [44]
b. Views on Therapeutic Environments (VOTE-Staff
measure) will be completed by staff pre and post
intervention and is implemented on the wards.
A 20-item questionnaire exploring the
perceptions of staff on inpatient wards, the
scale has good test-retest concordance, strong
internal consistency, criterion, face and content
validity [45]
7. Data required for cost analysis on service use:
a. EuroQol five dimensions (EQ-5D) is a NICE-
recommended measure that documents health
status required for quality-adjusted life-year
(QALY) estimation for primary economic analysis.
It assesses five domains of mobility, self-care, usual
activity, pain/distress, and anxiety/depression [46].
Health status profiles will be converted into utility
values using utility tariffs for EuroQol to estimate
QALYs [47]
b. Use of Services Inventory is a trial specific data
capturing form to collect data on service usage
during the study
c. Case notes review will be conducted to collect data
on service use for each participant to estimate costs.
Based on previous work in mental health, data on
service use for 3 months prior to entry to the study
will be collected
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Therapeutic alliance and treatment fidelity
The therapeutic alliance and engagement in therapy will
be measured using the Working Alliance Inventory
(WAI) (client and therapist version) [48], administered at
session 4 and post therapy. The WAI is a self-report
measure of the therapeutic bond, task agreement and
goal agreement with higher scores indicating a better
therapeutic alliance between client and therapist.
Data analysis
In accordance with the Consolidated Standards of Report-
ing Trials (CONSORT) principles [49], we will report all
participant flow. Demographic data will be described using
summary statistics (means and standard deviations or
number and percentage).
The main efficacy analysis is on an intention-to-treat
basis with data from all participants. Every effort will be
made to follow up all participants in both arms for assess-
ments and the analysis will use, where appropriate, statis-
tical techniques for handling missing data. Descriptive
statistics will be used to summarise the primary outcome
measures.
The secondary outcome measures will be analysed
using a linear regression model, allowing for the baseline
measurement of outcome, treatment assignment and
NHS trust as covariates, at each assessment point separ-
ately. The coefficient of the treatment assignment is an
estimate of the between-group treatment effect, and can
inform potential effect sizes for a future definitive trial.
Point estimates and associated 95 % confidence intervals
will be reported rather than tests of statistical signifi-
cance (p values).
Economic evaluation
A cost-effectiveness analysis will be performed to further
investigate the impact of CBSP for patients and health
and social care providers. Data on costs, service use and
health status will be collected. Unit costs for each type
of service will be derived from local and national data-
bases and statistics. The main outcome of interest for a
cost-effectiveness analysis is the likely cost-effectiveness
of the CBSP intervention. Secondary analysis of the data
will explore: the structural uncertainty associated with
the trial design; the extent to which EQ-5D scores and
QALY values are correlated with clinical outcome mea-
sures and discriminate between groups and sources of
external data. Baseline covariates in patient clinical and
socioeconomic characteristics and pre-study service use
will be controlled for. Factors known to influence costs
and QALYs (e.g. ethnicity, socioeconomic status) will be
collected at baseline to statistically control for their im-
pact. The data will also be used to inform sample size
decisions for a definitive trial.
Qualitative data
All interviews will be digitally audio-taped and transcribed
verbatim. An inductive approach using Thematic Analysis
[50] will be taken to elicit patterns within the data corpus
using standard procedures involving identifying meaning
codes and categories at both the semantic and latent level
[50]. Data generation and analysis will continue in parallel,
using the constant comparative technique. Disconfirming
evidence will be sought, until thematic category saturation
is achieved. Records of field notes will be maintained and
reflections providing adjunctive data will be used to illu-
minate and justify interpretative decisions.
Analysis will be primarily conducted by the experienced
qualitative applicants, but interim analysis will involve the
wider multi-disciplinary research team, including the
study’s service user reference group (SURG). Integrating
data from different stakeholders, and researcher triangula-
tion increases the trustworthiness of the final analysis [48].
Discussion
The strength of the INSITE pilot RCT is that it will be
one of the first to investigate the use of psychological
therapies in acute psychiatric wards including a range of
outcomes. It will explore key issues relating to experi-
ences of suicidal patients and pragmatic issues that will
inform a larger, definitive RCT that will examine the ef-
fectiveness of CBSP in inpatient settings, treatment up-
take and recruitment. A limitation of the study design
includes insufficient power to determine the effective-
ness of key suicidality outcomes. The study sample was
recruited from one mental health trust which is not rep-
resentative of the wider inpatient environment.
Some of the issues that will need to be addressed in-
clude whether it is possible to recruit sufficient numbers
of participants for a full-scale trial and to identify possible
reasons why patients may, or may not, want to participate
in the trial. We will discover if it is possible to retain par-
ticipants in the intervention, both during their inpatient
care and following discharge into the community. NHS
services are often criticised for failings in the continuity of
care, particularly for discharge from acute psychiatric
wards when there is an increased risk of suicide [1, 15].
Therapy that begins on the ward and continues into the
community may help to avoid such discontinuity. Work-
ing on the ward presents several challenges in itself and
there are few precedents of psychological therapy being
delivered in acute psychiatric settings. The study will in-
vestigate what features of ward activity need to be consid-
ered to successfully implement this intervention. CBSP
has been employed in a community setting and for pris-
oners, but this study will examine how the therapy should
be modified for acute inpatients.
It is also necessary to consider the most effective and
sensitive outcome measures to detect meaningful change
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resulting from CBSP. Existing instruments measuring sui-
cidal behaviours and ideas have limitations and may re-
quire refinement, particularly to reflect service-user
defined outcomes of recovery from suicidality. The study
would like to explore what training and support is re-
quired to maximise the contribution of service users to
suicidality research. In order to determine whether CBSP
is value for money, we will require data depicting the cost
of current treatment to compare it to. Evidence of value
for money is required to inform future NHS policy and
funding decisions regarding CBSP. This information will
have to be comprehensive to affect resource allocation. In
addition to the research aims outlined, we are interested
in the impact that the introduction of CBSP had on a
number of patient and staff outcomes, including: patient
experience of therapy; impact on suicidality; and ward staff
views on the use of CBSP in the inpatient setting.
Trial status
We are currently recruiting participants for our trial.
Additional file
Additional file 1: CONSORT 2010 checklist of information to include
when reporting a randomised trial*. (DOC 218 kb)
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